Purpose Novel multidrug resistance (mdr) modulators have been proved as inhibitors of P-
glycoprotein (P-gp). We first investigated the in vitro effects of selected compounds in human …

Multidrug resistance (MDR) is one of important issues to cause the chemotherapy failure
against cancers including gynecological malignancies. Despite some MDR reversal …

Abstract P-glycoprotein (P-gp)-mediated multidrug resistance (MDR) is a phenomenon in
which cells become resistant to structurally and mechanistically unrelated drugs resulting in …

Multidrug resistance (MDR) is a kind of acquired resistance of microorganisms and cancer
cells to chemotherapeutic drugs that are characterized by different chemical structure and …

The co-administration of anticancer drugs and P-glycoprotein (P-gp) inhibitors was a
treatment strategy to surmount multidrug resistance (MDR) in anticancer chemotherapy. In …

The resistance to chemotherapy of cancer cells is mediated by the overexpression of P-
glycoprotein, as an ATP-dependent membrane efflux pump. Two families of compounds …

Multidrug resistance (MDR) in cancer cells can lead to chemotherapeutic failure. The lack of
effective therapies has created a growing need for developing new and effective …

Aim: Enamino 3-benzazecine compounds, incorporating the C6-C8 allene system, were
synthesized and evaluated in vitro as inhibitors of P-glycoprotein (P-gp) and/or multidrug …

Multidrug resistance (MDR) to chemotherapeutic drugs is the main cause of chemotherapy
failure in cancer treatment, and it generally results from expression of ATP-dependent efflux …

P‐glycoprotein‐mediated drug efflux can yield a multidrug‐resistance (MDR) phenotype that
is associated with a poor response to cancer chemotherapy. Development of safe and …